- About us
- About Vaccines
- Media centre
- Become a member
- We-Wont-Rest campaign
Europe is at the heart of global vaccine research and production. Most of the activities of the major innovative Vaccines Europe members research based-companies are based in the region.
Effective vaccination programmes ease pressure on budgets and allow resources to focus on other healthcare areas and medical innovation
Vaccination at the Heart of Public Health. Vaccines Europe calls on EU policy-makers to develop a comprehensive vaccination strategy through five core policy asks.
As the EU-wide recognised vaccine industry stakeholder, Vaccines Europe represents major innovative research-based vaccine companies operating in Europe as well as small and medium sized enterprises.
Find out more about our services, the opportunites we offer and how to become a member.
The associations representing the European and British life science industry (AESGP, ABPI, BIA, BGMA, EBE, EFPIA, EUCOPE, EuropaBio, Medicines for Europe, PAGB, Vaccines Europe) have today launched a joint policy document on the potential impact of the United Kingdom’s exit the European Union.
Access the document here and access the Press Release below under Read more.
Vaccines Europe launched the We-Wont-Rest Campaign in November 2017. The new campaign focuses on the passion, commitment and dedication of individuals, teams and companies in the vaccine industry to discovering and developing new vaccines for patients. We’re telling our industry’s innovation story and using #WeWontRest to start the public discussion on the value of innovation and the future of healthcare in Europe.
Access the campaign page here and read about the pledges industry experts have made here.
The Early Career Research Prize in Vaccinology R&D is awarded by the International Union of Immunological Societies (IUIS) with the contribution of Vaccines Europe. The objective is to promote and foster a younger generation of scientists in the early stages of their career.
The prize rewards significant achievements in Vaccine R&D, including the discovery of new vaccine antigens, new vaccines design, understanding the basics of the immune response, new technologies that will improve the future of vaccines and vaccination and that are supported by proof-of-concept data (preclinical and clinical).
Vaccines Europe is pleased to announce that Pascale Mauran, Vice-President, IDM Vaccines Commercial Development at Pfizer, has been officially appointed as the new Vaccines Europe President. Pascale Mauran has been representing Pfizer on the Vaccines Europe Board for four years now, out of which one and half year as Vaccines Europe Vice-President. She brings solid experience and expertise on vaccines to help drive the development of the Vaccines Europe objectives. Pascale Mauran’s appointment as President will start immediately and will run for the next two years.
Pascale Mauran stated: “I am delighted to take the responsibility of President of Vaccines Europe and continue to drive Vaccines Europe strategy and vision in this significant momentum for vaccination in Europe with the EU Joint Action on Vaccination and all other important EU initiatives underway”.
Vaccines Europe expresses its gratitude to its former President Andrea Rappagliosi, for his strong leadership dedicated to Vaccines Europe over the past 5 years.
For more information, please contact:
Magdalena R. de Azero, Executive Director, Vaccines Europe